IBS treatment market set to reach $10.65 billion by 2030

By AI, Created 1:12 PM UTC, June 04, 2026, /AGP/ – The global irritable bowel syndrome treatment market is projected to grow from $7.41 billion in 2025 to $7.97 billion in 2026, with North America holding the largest share and Europe expected to grow fastest. The Business Research Company says gains will be driven by precision medicine, digital health, microbiome research and online pharmacy adoption.

Why it matters: - IBS treatment demand is rising as more patients are diagnosed and more providers offer prescription therapies. - The market outlook points to steady growth in digestive health care, with new tools aimed at improving symptom control and patient quality of life. - Faster adoption of digital health, precision medicine and microbiome-based therapies could change how IBS is managed over the next several years.

What happened: - The Business Research Company released its IBS Treatment Market Report 2026, covering market size, trends and global forecasts through 2035. - The report puts the IBS treatment market at $7.41 billion in 2025 and $7.97 billion in 2026, a 7.6% compound annual growth rate. - The forecast calls for the market to reach $10.65 billion by 2030, growing at 7.5% annually. - North America held the largest market share in 2025. - Europe is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also pointed readers to a free sample report and the full market report.

The details: - IBS treatment includes medical strategies used to manage gastrointestinal disorders. - The treatments are designed to relieve constipation, diarrhea and abdominal pain. - The goal is to reduce the frequency and intensity of flare-ups. - The report ties recent growth to higher gastrointestinal disorder rates, better IBS diagnosis, stronger public awareness of digestive health and wider availability of prescription medication. - Hospital and retail pharmacy network expansion also supports market growth. - Looking ahead, the company cites precision medicine, digital health platforms, online pharmacy sales, microbiome research and higher spending on chronic disease care as key growth drivers. - The report highlights microbiome-based therapies, digital therapeutics, AI-driven diagnostic tools, remote patient monitoring, smart gut health devices and patient-focused drug development as major trends.

Between the lines: - The market shift reflects a move from symptom management toward more personalized and data-driven care. - Digital tools and online distribution could make IBS treatment easier to access, especially for patients managing a chronic condition over time. - The emphasis on microbiome research suggests the field is looking for new therapeutic pathways beyond traditional medications. - The report’s regional split suggests mature markets still dominate revenue while Europe may gain ground through continued investment and innovation.

What’s next: - The market is projected to keep expanding through 2030 as precision medicine and digital care tools gain traction. - More product development is likely around microbiome therapies, remote monitoring and AI-assisted treatment optimization. - The Business Research Company also listed related reports on inflammatory bowel disease treatment, bowel management systems and constipation treatment.